Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 8/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.64 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.64 |
| ▸ | GLA | P06280 | 2/20 | 0.64 |
| ▸ | HPGD | P15428 | 2/20 | 0.64 |
| ▸ | CASP1 | P29466 | 2/20 | 0.64 |
| ▸ | CASP7 | P55210 | 2/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.64 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.64 |
| ▸ | MAOA | P21397 | 2/20 | 0.64 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.64 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.64 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.64 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.64 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.64 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.64 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.64 |
| ▸ | NQO2 | P16083 | 1/20 | 0.64 |
| ▸ | DRD1 | P21728 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30583435 | 1.00 | ACHE (0.64) | ACHEALDH1A1HSD17B10KDM4EGLA | |
| Hydrochloric Acid SCHEMBL843193 | 0.98 | RAB9A (0.65) | ACHEALDH1A1HSD17B10KDM4EGLA | |
| SCHEMBL12874595 | 0.85 | MAOA (0.61) | ACHEALDH1A1HSD17B10KDM4EGLA | |
| SCHEMBL15978466 | 0.82 | ALDH1A1 (0.52) | ACHEALDH1A1HSD17B10KDM4EGLA | |
| Aminacrine SCHEMBL14999 | 0.79 | HSD17B10 (1.00) | ACHEALDH1A1HSD17B10KDM4EGLA | |
| Aminacrine SCHEMBL29354393 | 0.79 | HSD17B10 (1.00) | ACHEALDH1A1HSD17B10KDM4EGLA | |
| SCHEMBL16021109 | 0.77 | KDM1A (0.47) | ACHEALDH1A1HSD17B10KDM4EGLA | |
| SCHEMBL4059507 | 0.77 | HSD17B10 (0.52) | ACHEALDH1A1HSD17B10KDM4EGLA | |
| SCHEMBL29809559 | 0.77 | HSD17B10 (0.70) | ACHEALDH1A1HSD17B10KDM4EGLA | |
| SCHEMBL841779 | 0.77 | HSD17B10 (0.70) | ACHEALDH1A1HSD17B10KDM4EGLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4499641-A1 | A3 ADENOSINE RECEPTOR POSITIVE ALLOSTERIC MODULATORS | The United States of America, as represented by the Secretary, Department of Health and Human Services (US) | 2025-02-05 | — | — | EP | disclosed |
| WO-2023192408-A1 | A3 ADENOSINE RECEPTOR POSITIVE ALLOSTERIC MODULATORS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2023-10-05 | — | — | WO | disclosed |
| WO-2023192408-A1 | A3 ADENOSINE RECEPTOR POSITIVE ALLOSTERIC MODULATORS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2023-10-05 | — | — | WO | disclosed |
| WO-2022161420-A1 | CLASS OF HETEROAROMATIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | 上海翊石医药科技有限公司 | 2022-08-04 | — | — | WO | disclosed |
| EP-1948173-B1 | HYDROXY AND ALKOXY SUBSTITUTED 1H-IMIDAZOQUINOLINES AND METHODS | 3M INNOVATIVE PROPERTIES CO (US) | 2013-07-17 | — | — | EP | disclosed |
| US-8377957-B2 | Hydroxy and alkoxy substituted 1H-imidazoquinolines and methods | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2013-02-19 | — | — | US | disclosed |
| US-8143270-B2 | 2-amino 1H-in-imidazo ring systems and methods | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2012-03-27 | — | — | US | disclosed |
| US-20120071463-A1 | HYDROXY AND ALKOXY SUBSTITUTED 1H-IMIDAZOQUINOLINES AND METHODS | 3M INNOVATIVE PROPERTIES COMPANY | 2012-03-22 | — | — | US | disclosed |
| US-8088790-B2 | Hydroxy and alkoxy substituted 1H-imidazoquinolines and methods | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2012-01-03 | — | — | US | disclosed |
| US-7915281-B2 | Isoxazole, dihydroisoxazole, and oxadiazole substituted imidazo ring compounds and method | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2011-03-29 | — | — | US | disclosed |
| EP-1339715-A2 | HETEROCYCLIC ETHER SUBSTITUTED IMIDAZOQUINOLINES | 3M Innovative Properties Company (US) | 2003-09-03 | — | — | EP | disclosed |
| US-20030139441-A1 | Sulfonamido ether substituted imidazoquinolines | UBS AG, STAMFORD BRANCH | 2003-07-24 | — | — | US | disclosed |
| US-20030065005-A1 | Heterocyclic ether substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2003-04-03 | — | — | US | disclosed |
| US-20020193396-A1 | Sulfonamido ether substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2002-12-19 | — | — | US | disclosed |
| WO-2002046193-A2 | HETEROCYCLIC ETHER SUBSTITUTED IMIDAZOQUINOLINES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2002-06-13 | — | — | WO | disclosed |
| WO-2002046189-A2 | ARYL ETHER SUBSTITUTED IMIDAZOQUINOLINES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2002-06-13 | — | — | WO | disclosed |
| WO-2002046190-A2 | SULFONAMIDO ETHER SUBSTITUTED IMIDAZOQUINOLINES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2002-06-13 | — | — | WO | disclosed |
| US-5756747-A | 1H-imidazo 4,5-c!quinolin-4-amines | RIKER LABORATORIES, INC. (US) | 1998-05-26 | — | — | US | disclosed |
| EP-0385630-B1 | 1H-imidazo(4,5-c)Quinolin-4-amines as antivirals | RIKER LABORATORIES INC (US) | 1996-11-27 | — | — | EP | disclosed |
| EP-0385630-A2 | 1H-imidazo(4,5-c)Quinolin-4-amines as antivirals | RIKER LABORATORIES, INC. (US) | 1990-09-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030065005-A1 | Heterocyclic ether substituted imidazoquinolines | IFNG, IL2, IRF3 | ACHE 4670/4885ALDH1A1 2486/4885HSD17B10 3488/4885 |
| US-20030139441-A1 | Sulfonamido ether substituted imidazoquinolines | IFNG, IRF3, IL2 | ACHE 4783/4885ALDH1A1 2448/4885HSD17B10 4364/4885 |
| US-20120071463-A1 | HYDROXY AND ALKOXY SUBSTITUTED 1H-IMIDAZOQUINOLINES AND METHODS | IFNG, IL2, IRF3 | ACHE 4256/4885ALDH1A1 517/4885HSD17B10 1013/4885 |
| US-20020193396-A1 | Sulfonamido ether substituted imidazoquinolines | IFNG, IRF3, IL2 | ACHE 4783/4885ALDH1A1 2448/4885HSD17B10 4364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.